Apr 27, 2016

Posted by in Biotech Stocks | 0 Comments

Notable Runners: Geron Corporation (NASDAQ:GERN), Macrocure Ltd (NASDAQ:MCUR), Halozyme Therapeutics Inc (NASDAQ:HALO)

Notable Runners: Geron Corporation (NASDAQ:GERN), Macrocure Ltd (NASDAQ:MCUR), Halozyme Therapeutics Inc (NASDAQ:HALO)

Geron Corporation (NASDAQ:GERN) stock is at $3.11, down -3.12 percent from its previous close of $3.21. The stock opened the session at $3.23 and touched its highest price point at $3.34. The company’s stock’s lowest price point for the session stood at $3.06. Its yesterday’s volume was 2.06 million shares in comparison to its usual trading volume of 2.15 million shares.

Geron Corporation (NASDAQ:GERN) on April 20, 2016 announced two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, at the 2016 American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, Louisiana. The first poster presentation described results that treating acute myeloid leukemia (AML) cell lines with imetelstat enhanced the effects of agents currently used for the treatment of AML. These data extend the rationale from prior non-clinical studies for the potential use of imetelstat in hematologic myeloid malignancies, such as AML, including in combination with standard therapies. The second poster presentation described results from non-clinical studies that provide further evidence of potential on-target mechanisms of telomerase inhibition by imetelstat underlying the reduction in platelets observed in previously conducted imetelstat clinical trials.

Macrocure Ltd (NASDAQ:MCUR) stock is at $1.37, down -17.47 percent from its previous close of $1.66. Its yesterday’s volume was 7.16 million shares in comparison to its usual trading volume of 294,662.00 shares. Previous 5 days graph demonstrated a positive move of 39.8%. Its quarterly performance remained green with the percentage of 22.32, while its year to date performance showed that the stock advanced overall 6.2%.

Macrocure Ltd (NASDAQ:MCUR), a biotechnology company, focuses on developing, manufacturing, and commercializing novel cell therapy products for the treatment of chronic and other hard-to-heal wounds in Israel. Macrocure Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

Halozyme Therapeutics Inc (NASDAQ:HALO) traded in the range of $10.85 and $12.31 in its previous trading session. The stock recorded the volume of 1.75 million shares so far, in comparison its average daily trading volume of 1.75 million shares. Company’s year to date performance remained declining as it lost almost -35.59%. The stock opened at $11.91 and its closing price for the day was $11.22, down -5.87 percent from its previous close.

Halozyme Therapeutics Inc (NASDAQ:HALO) on April 20, 2016 reported that it will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2016.

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies.


Comments are closed.